Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study
Published: 9 January 2019| Version 1 | DOI: 10.17632/ffg8fv5ph5.1
Contributors:
Antonio Llombart, Antonio Antón, Isabel Garau, Mirta García, José Juan Illarramendi, Cesar Rodriguez, Noemia Afonso, Elena Aguirre, Pilar Zamora, Miguel Sampayo, Vanesa Ortega, Esperanza Blanco, María Martínez-García, Javier Cortes, Lourdes Calvo, Jose Perez Garcia, Yolanda FernándezDescription
A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study
Files
Categories
Oncologist, Publication